Yamanouchi Will Promote Vesicare With 150 Specialty Sales Reps

FDA clears Vesicare for the treatment of overactive bladder. Yamanouchi and co-promotion partner GlaxoSmithKline will launch solifenacin in January 2005, with GSK sales reps handling primary care duties and Yamanouchi reps detailing to urologist and ob/gyns.